Russian scientists are preparing to deliver personalized melanoma vaccines to ten patients within the next one to three months. The vaccines are being developed by researchers at the Gamaleya National Research Center for Epidemiology and Microbiology, led by Academician Alexander Gintsburg. This initiative represents a significant step forward in personalized cancer treatment within Russia. Gintsburg stated the vaccines are specifically tailored to individual patients, suggesting a focus on neoantigen-based therapies. The development process has progressed rapidly, indicating a dedicated effort to address melanoma, a dangerous form of skin cancer. This project highlights Russia's growing capabilities in biotechnology and its commitment to combating serious diseases. Further details regarding the vaccine's composition and clinical trial phases have not yet been disclosed.